P53&AMCR over-expression accelerate dysplastic progression in CMV ulcerative colitis patients (a comparative study of CMV and Non-CMV ulcerative colitis)
Alabiad, M., Fakhr, A., Mohamed, A., Gomaa, A., Shalaby, A., Nosery, Y., Gobran, M. (2022). P53&AMCR over-expression accelerate dysplastic progression in CMV ulcerative colitis patients (a comparative study of CMV and Non-CMV ulcerative colitis). EKB Journal Management System, 28(4), 748-761. doi: 10.21608/zumj.2020.47756.1983
Mohamed Ali Alabiad; Ahmed Elsadek Fakhr; Ahmed Said Mohamed; Ahmed Fathy Gomaa; Amany Mohamed Shalaby; Yousef Nosery; Mai Ahmed Gobran. "P53&AMCR over-expression accelerate dysplastic progression in CMV ulcerative colitis patients (a comparative study of CMV and Non-CMV ulcerative colitis)". EKB Journal Management System, 28, 4, 2022, 748-761. doi: 10.21608/zumj.2020.47756.1983
Alabiad, M., Fakhr, A., Mohamed, A., Gomaa, A., Shalaby, A., Nosery, Y., Gobran, M. (2022). 'P53&AMCR over-expression accelerate dysplastic progression in CMV ulcerative colitis patients (a comparative study of CMV and Non-CMV ulcerative colitis)', EKB Journal Management System, 28(4), pp. 748-761. doi: 10.21608/zumj.2020.47756.1983
Alabiad, M., Fakhr, A., Mohamed, A., Gomaa, A., Shalaby, A., Nosery, Y., Gobran, M. P53&AMCR over-expression accelerate dysplastic progression in CMV ulcerative colitis patients (a comparative study of CMV and Non-CMV ulcerative colitis). EKB Journal Management System, 2022; 28(4): 748-761. doi: 10.21608/zumj.2020.47756.1983

P53&AMCR over-expression accelerate dysplastic progression in CMV ulcerative colitis patients (a comparative study of CMV and Non-CMV ulcerative colitis)

Zagazig University Medical Journal
Article 18, Volume 28, Issue 4, July 2022, Page 748-761  XML PDF (973.24 K)
Document Type: Original Article
DOI: 10.21608/zumj.2020.47756.1983
View on SCiNiTO View on SCiNiTO
Authors
Mohamed Ali Alabiad email orcid 1; Ahmed Elsadek Fakhrorcid 2; Ahmed Said Mohamed3; Ahmed Fathy Gomaa4; Amany Mohamed Shalaby5; Yousef Nosery6; Mai Ahmed Gobran7
1Pathology Department, Faculty of Medicine, Zagazig University
2Microbiology and Immunology Department, Faculty of Medicine, Zagazig University, Egypt
3Tropical Medicine Department, Faculty of Medicine, Zagazig University
4Internal Medicine, Faculty of Medicine, Zagazig University, Egypt
5Histology and Cell Biology Department, Faculty of Medicine, Tanta University, Egypt
6Pathology Department, Faculty of Medicine, Zagazig University, Egypt.
7Pathology Department, Faculty of Medicine, Zagazig University, Egypt
Abstract
Background: CMV Virus is one of the most common opportunistic infections in ulcerative colitis patients that leads to more immunological and inflammatory irritations and thus leads to treatment resistance and dysplastic progression
Objective: This work aims to evaluate the role of P53 & AMACR as early predictor markers of dysplastic transformation, and clinical deterioration in CMV infected ulcerative colitis patients.
Design: Forty CMV-ulcerative colitis and twenty Non CMV-ulcerative colitis patients with active colitis underwent baseline assessment for clinical endoscopic evaluation, histological evaluation of the degree of inflammation and dysplasia and P53/AMACR expression detection. Cases were then classified into four groups, namely CMV-UC with P53/AMACR, CMV-UC without P53/AMACR, Non CMV-UC with P53/AMACR and Non CMV-UC without P53/AMACR. After 36.16±3.78 months of follow up the same assessment was carried out to record progression parameters of all groups.
Results: CMV-UC with P53&AMACR group showed a significant association with clinical, histological progression 8/22 (36.4%) in compared with CMV-UC without P53/AMACR the clinical and histological progression were 1/18 (5.6%) and 2/18 (11.1%) respectively and in Non CMV-UC with P53/AMACR group were 1/9 (11.1%) and 2/9 (22.2%) respectivly with (P-value
Keywords
P53; AMACR; CMV; dysplasia; ulcerative colitis
Statistics
Article View: 287
PDF Download: 169